XHEL
REG1V
Market cap449mUSD
Sep 17, Last price
13.46EUR
1D
3.06%
1Q
7.51%
Jan 2017
32.48%
IPO
2,275.28%
Name
Revenio Group Oyj
Chart & performance
P/E
22.50
P/S
3.57
EPS
0.60
Div yield, %
2.97%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
12.43%
Revenues
110m
+5.99%
Net income
17m
-5.93%
CFO
30m
+26.50%
Dividend
Apr 11, 20250.4 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Revenio Group Oyj operates as a healthcare technology company, specializing in the development, production, and global distribution of advanced ophthalmic diagnostic instruments and medical devices. These innovations are engineered to aid in the identification of various eye conditions, including glaucoma, macular degeneration, diabetic retinopathy, and cataracts, serving clientele in Finland, throughout Europe, and worldwide. Its extensive product portfolio includes the iCare IC100 and IC200 tonometers, along with the iCare HOME device for personal eye pressure monitoring. Furthermore, the company provides sophisticated imaging technologies such as the iCare EIDON AF for confocal retinal imaging, DRSplus for screening diabetic retinopathy, the iCare MAIA microperimeter for precise visual field measurements, and iCare COMPASS, which facilitates fundus perimetry using true-color retinal images. Beyond hardware, Revenio also offers Oculo, a comprehensive eye care software platform that seamlessly integrates clinical communication, telehealth functionalities, remote patient monitoring, and robust data analytics. Established in 2001, Revenio Group Oyj is based in Vantaa, Finland.
Key people
Robin Pulkkinen
Chief Financial Officer, Member of the Management Team · since 2015
John Floyd
Chief Executive Officer of Icare USA · since 2016
Tomi Karvo
Sales and Marketing Director, Member of the Management Team · since 2016
Ari Kukkonen
Senior Advisor · since 2018
Giuliano Barbaro
R&D Director of Imaging Devices, Member of the Management Board · since 2020
Ari Isomaki
Icare Finland Ltd Operations Director, Member of the Management Team, · since 2016
Jasmin Kuittinen
Member of the Management Team, Acting Chief Financial Officer · since 2014
Tiina Olkkonen
External Communications Specialist, Member of the Management Team, Secretary · since 2016
Mika Salkola
Revenio Research Oy's R&D Director, Member of the Group Management Team · since 2018
Heli Valtanen
Icare Finland Ltd's QA Manager, Member of the Group Management Team · since 2018
Kyosti Kakkonen
Independent Director · since 2014
Ari Kohonen
Independent Director · since 2013
Independent Chairman of the Board · since 2018
Headquarters & legal address
Härkähaankuja 7
01730 VANTAA
VANTAA FI-01730
FI
01730 VANTAA
VANTAA FI-01730
FI
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||